Delivery Order SPE2DR25D2104-SPE2DR26F3PAS
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $15,080.57 to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalers (60-count units) with a completion date of September 30, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is issued as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $7,668.28 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count) with a completion date of November 17, 2025. This contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. The order will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania, where the company maintains its headquarters and primary operations for federal...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count) with a ceiling value of $4,180.59 under a firm fixed-price contract type. The order was competitively awarded without set-aside designation and is scheduled for completion by September 12, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order represents a child...
- The Defense Logistics Agency awarded a $40,498.66 firm fixed price delivery order to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) on July 25, 2025, with an ultimate completion date of July 28, 2025. The contract, which carries no set-aside designation, was competitively awarded and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under...
- The Defense Logistics Agency awarded a delivery order valued at $5,773.90 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count) on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price delivery order, issued without a set-aside designation, represents a competitively awarded transaction under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $41,926.54 for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) on August 21, 2025, with completion scheduled for August 22, 2025. This is a firm fixed-price, non-set-aside award that represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be...
- The Defense Logistics Agency awarded a $12,545.94 delivery order to AmerisourceBergen Drug Corp for TRELEGY ELLIPTA 200-62.5-25 inhalers (60-count units) on July 31, 2025, with an ultimate completion date of August 1, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $16,076.36 to AmerisourceBergen Drug Corp for Trelegy Ellipta 200-62.5-25 inhalers (60-count) on September 12, 2025, with an ultimate completion date of September 15, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract issued under...
- The Defense Logistics Agency awarded a $6,220.79 delivery order to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) with an ultimate completion date of September 3, 2025. This is a firm fixed-price delivery order under a competitive award with no set-aside designation. The product will be delivered to the vendor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a single transaction within AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order valued at $6,090.36 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count) with a completion date of June 18, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the contractor's facility in Conshohocken, Pennsylvania. This...
- SPE2DR25D2104Indefinite Delivery Contract
- SPE2DR25D2104-SPE2DR26F3PASDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $5,607.60 to AmerisourceBergen Drug Corp for Trelegy Ellipta 100-62.5-25 inhalers (60-count units) with a completion date of November 14, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and represents a child contract action under AmerisourceBergen's larger federal contract portfolio. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor contract running through December 2026 that provides comprehensive pharmaceutical support to military healthcare systems globally. As a major pharmaceutical distributor, AmerisourceBergen supplies a wide range of medications, vaccines, and medical supplies to federal customers including the Defense Health Agency and U.S. Coast Guard. Trelegy Ellipta is a combination respiratory medication used in chronic obstructive pulmonary disease treatment, consistent with the company's portfolio of specialty medications supporting military medical needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.6k | 11/13/25 |